---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011424"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:44:54.133320+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Director John Canan resigns from Acasti Pharma board, no dispute

## Summary
- Jean-Marie (John) Canan resigned from the board effective March 30, 2023.
- Canan was a member of the audit committee and governance and human resources committee.
- Resignation was not due to any dispute or disagreement with the Company or board.

## SEC filing metadata
- accession: 0000950170-23-011424
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023011424/0000950170-23-011424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023011424/acst-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011424
- JSON: https://secwatch.observer/filing/0000950170-23-011424.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011424.txt

## Key facts
- Executive change
  Jean-Marie (John) Canan resigned as director at Grace Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: On March 30, 2023, Mr. Jean-Marie (John) Canan resigned from the board of directors of Acasti Pharma Inc. (the "Company"), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023011424/0000950170-23-011424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.